

27 March 2024

Oncology Supplemental

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

CAPOX (Capecitabine with Oxaliplatin)		<5
FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)		<5
Lonsurf (Trifluridine - tipiracil)		<5
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)		<5
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)		<5
Any other systemic anti-cancer therapy	Carboplatin	<5
	CX 60/625 & Trazimera	<5
	Etoposide and Carbo	<5
	Flot	37
	IMDG	5
	Nivolumab OX	<5
	OMDG	<5
	OX 80/375 & Trazimera	5
	OX 80/375	28
	Pemmbrolizumab	<5
	Pembrolizumab CX	<5
	Pembrolizumab OX	6
	P-TCX	<5
Palliative care only	Not available on RISOH	

Q2. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

Atezolizumab (Tecentriq)		<5
Durvalumab (Imfinzi)		<5
Nivolumab (Opdivo)		<5
Pembrolizumab (Keytruda)		13
Chemotherapy	Cisplatin & Vinorelbine	<5
	Docetaxel	<5
	Gemcitabine & Carboplatin	<5

27 March 2024

	Nintedanib & Docetaxe	<5
	Nintedanib Monotherapy	<5
	Nivolumab/Paclitaxel/Carboplatin	<5
	Osimertinib	<5
	Pembrolizumab/Pmetrexed/Carbo	<5
Radiotherapy	Not available on RISOH	
Chemotherapy AND Radiotherapy	Carboplatin & Vinorelbine XRT	<5
	Cisplatin & Vinorelbine XRT	<5
	Paclitaxel & Carboplatin XRT 13	13

Q3. In the past three months, how many advanced renal cell carcinoma patients received the following first-line treatments:

Avelumab + Axitinib (Bavencio + Inlyta)	<5
Cabozantinib (Cometriq)	15
Nivolumab (Opdivo)	15
Nivolumab + Cabozantinib (Opdivo + Cometriq)	16
Nivolumab + Ipilimumab (Opdivo + Yervoy)	<5
Pembrolizumab + Lenvatinib (Keytruda + Kispilix)	<5

Where numbers are low, we have used <5 rather than release the exact figure. This is because doing so has the potential to make those people identifiable, and so those figures are exempt from release under Section 40(2) of the FOI Act which relates to personal Information relating to a third party.